Acer Therapeutics (NASDAQ:ACER – Get Rating) will be announcing its earnings results on Tuesday, February 28th.
Acer Therapeutics Price Performance
ACER opened at $2.14 on Monday. The company’s 50 day moving average is $2.57 and its 200 day moving average is $1.85. Acer Therapeutics has a 12-month low of $1.11 and a 12-month high of $4.56.
Insider Buying and Selling at Acer Therapeutics
In related news, CEO Chris Schelling purchased 819,672 shares of the company’s stock in a transaction that occurred on Tuesday, November 29th. The stock was bought at an average price of $1.22 per share, for a total transaction of $999,999.84. Following the completion of the transaction, the chief executive officer now owns 2,712,529 shares in the company, valued at approximately $3,309,285.38. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 20.20% of the company’s stock.
Institutional Investors Weigh In On Acer Therapeutics
Several large investors have recently added to or reduced their stakes in ACER. Geode Capital Management LLC grew its stake in Acer Therapeutics by 6.1% during the 4th quarter. Geode Capital Management LLC now owns 96,330 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 5,515 shares during the last quarter. Renaissance Technologies LLC raised its position in Acer Therapeutics by 216.8% during the second quarter. Renaissance Technologies LLC now owns 69,700 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 47,700 shares during the period. Meridian Wealth Management LLC acquired a new position in shares of Acer Therapeutics during the fourth quarter valued at approximately $180,000. Finally, Vanguard Group Inc. boosted its stake in Acer Therapeutics by 55.5% during the 1st quarter. Vanguard Group Inc. now owns 278,215 shares of the biopharmaceutical company’s stock worth $807,000 after purchasing an additional 99,335 shares during the last quarter. 27.96% of the stock is owned by hedge funds and other institutional investors.
